 | • レポートコード：MRC2304J0206 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、247ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医療 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社の本調査資料によると、世界のポイントオブケア（POC）分子診断市場規模は、2021年389.12百万ドルから2022年に424.80百万ドルへと拡大、その後2027年までに年平均9.42％成長して668.00百万ドルに達する見通しです。本書は、ポイントオブケア（POC）分子診断の世界市場を対象とした調査・分析結果を整理したものであり、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、製品別分析（分析装置、キット＆アッセイ、ソフトウェア＆サービス）、技術別分析（等温核酸増幅技術（INAAT）、リアルタイムポリメラーゼ連鎖反応（RT-qPCR））、用途別分析（院内感染（HAI）、新生児検査、腫瘍、呼吸器疾患、性感染症（STD））、エンドユーザー別分析（クリニック＆診断検査室、病院外来＆集中治療室（ICU）、研究＆学術機関）、地域別分析（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）、競争状況、企業情報などの項目を掲載しています。なお、本書には、Abbott Laboratories、Becton, Dickinson and Company、binx health, inc.、Biocartis NV、bioMérieux SA、Cardinal Health, Inc.、Co-Diagnostics, Inc.、Danaher Corporation、F. Hoffmann-La Roche AG、Genomadix、Lucira Health, Inc.などの企業情報が含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界のポイントオブケア（POC）分子診断市場規模：製品別 - 分析装置の市場規模 - キット＆アッセイの市場規模 - ソフトウェア＆サービスの市場規模 ・世界のポイントオブケア（POC）分子診断市場規模：技術別 - 等温核酸増幅技術（INAAT）の市場規模 - リアルタイムポリメラーゼ連鎖反応（RT-qPCR）の市場規模 ・世界のポイントオブケア（POC）分子診断市場規模：用途別 - 院内感染（HAI）における市場規模 - 新生児検査における市場規模 - 腫瘍における市場規模 - 呼吸器疾患における市場規模 - 性感染症（STD）における市場規模 ・世界のポイントオブケア（POC）分子診断市場規模：エンドユーザー別 - クリニック＆診断検査室における市場規模 - 病院外来＆集中治療室（ICU）における市場規模 - 研究＆学術機関における市場規模 ・世界のポイントオブケア（POC）分子診断市場規模：地域別 - 南北アメリカのポイントオブケア（POC）分子診断市場規模 アメリカのポイントオブケア（POC）分子診断市場規模 カナダのポイントオブケア（POC）分子診断市場規模 ブラジルのポイントオブケア（POC）分子診断市場規模 ... - アジア太平洋のポイントオブケア（POC）分子診断市場規模 日本のポイントオブケア（POC）分子診断市場規模 中国のポイントオブケア（POC）分子診断市場規模 インドのポイントオブケア（POC）分子診断市場規模 韓国のポイントオブケア（POC）分子診断市場規模 台湾のポイントオブケア（POC）分子診断市場規模 ... - ヨーロッパ/中東/アフリカのポイントオブケア（POC）分子診断市場規模 イギリスのポイントオブケア（POC）分子診断市場規模 ドイツのポイントオブケア（POC）分子診断市場規模 フランスのポイントオブケア（POC）分子診断市場規模 ロシアのポイントオブケア（POC）分子診断市場規模 ... - その他地域のポイントオブケア（POC）分子診断市場規模 ・競争状況 ・企業情報 |
The Global Point of Care Molecular Diagnostics Market size was estimated at USD 389.12 million in 2021 and expected to reach USD 424.80 million in 2022, and is projected to grow at a CAGR 9.42% to reach USD 668.00 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Point of Care Molecular Diagnostics to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Product, the market was studied across Analyzers, Kits & Assays, and Software & Services.
Based on Technology, the market was studied across Isothermal Nucleic Acid Amplification Technology (INAAT) and Real-Time Polymerase Chain Reaction (RT-qPCR).
Based on Application, the market was studied across Hospital Acquired Infections (HAIs), Neonatal Testing, Oncology, Respiratory Diseases, and Sexually Transmitted Diseases (STDs).
Based on End-User, the market was studied across Clinics and Diagnostic Laboratories, Hospital Outpatient Departments & Intensive Care Units (ICUs), and Research & Academic Institutes.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Point of Care Molecular Diagnostics market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Point of Care Molecular Diagnostics Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Point of Care Molecular Diagnostics Market, including Abbott Laboratories, Becton, Dickinson and Company, binx health, inc., Biocartis NV, bioMérieux SA, Cardinal Health, Inc., Co-Diagnostics, Inc., Danaher Corporation, F. Hoffmann-La Roche AG, Genomadix, Lucira Health, Inc., Meridian Bioscience Inc., Novartis AG, OraSure Technologies, Inc., Plexus Corp., QIAGEN GmbH, Siemens Healthineers AG, Thermo Fisher Scientific Inc., and Visby Medical, Inc..
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Point of Care Molecular Diagnostics Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Point of Care Molecular Diagnostics Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Point of Care Molecular Diagnostics Market?
4. What is the competitive strategic window for opportunities in the Global Point of Care Molecular Diagnostics Market?
5. What are the technology trends and regulatory frameworks in the Global Point of Care Molecular Diagnostics Market?
6. What is the market share of the leading vendors in the Global Point of Care Molecular Diagnostics Market?
7. What modes and strategic moves are considered suitable for entering the Global Point of Care Molecular Diagnostics Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of infectious diseases, hospital acquired infections (HAIs), and cancer
5.1.1.2. Growing awareness and acceptance of advanced therapeutic and diagnostic choices
5.1.1.3. Rapid use of molecular diagnostics for home healthcare
5.1.2. Restraints
5.1.2.1. Inadequate reimbursement scenario
5.1.3. Opportunities
5.1.3.1. Growing popularity of mHealth for allergy diagnosis offering the affordability of diagnosis
5.1.3.2. Technological advancements in DNA sequencing and analysis
5.1.4. Challenges
5.1.4.1. Stringent and time-consuming regulatory policies
5.2. Cumulative Impact of COVID-19
6. Point of Care Molecular Diagnostics Market, by Product
6.1. Introduction
6.2. Analyzers
6.3. Kits & Assays
6.4. Software & Services
7. Point of Care Molecular Diagnostics Market, by Technology
7.1. Introduction
7.2. Isothermal Nucleic Acid Amplification Technology (INAAT)
7.3. Real-Time Polymerase Chain Reaction (RT-qPCR)
8. Point of Care Molecular Diagnostics Market, by Application
8.1. Introduction
8.2. Hospital Acquired Infections (HAIs)
8.3. Neonatal Testing
8.4. Oncology
8.5. Respiratory Diseases
8.6. Sexually Transmitted Diseases (STDs)
9. Point of Care Molecular Diagnostics Market, by End-User
9.1. Introduction
9.2. Clinics and Diagnostic Laboratories
9.3. Hospital Outpatient Departments & Intensive Care Units (ICUs)
9.4. Research & Academic Institutes
10. Americas Point of Care Molecular Diagnostics Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Point of Care Molecular Diagnostics Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Point of Care Molecular Diagnostics Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.1.1. Quadrants
13.1.2. Business Strategy
13.1.3. Product Satisfaction
13.2. Market Ranking Analysis, By Key Player
13.3. Market Share Analysis, By Key Player
13.4. Competitive Scenario
13.4.1. Merger & Acquisition
13.4.2. Agreement, Collaboration, & Partnership
13.4.3. New Product Launch & Enhancement
13.4.4. Investment & Funding
13.4.5. Award, Recognition, & Expansion
14. Company Usability Profiles
14.1. Abbott Laboratories
14.1.1. Business Overview
14.1.2. Key Executives
14.1.3. Product & Services
14.2. Becton, Dickinson and Company
14.2.1. Business Overview
14.2.2. Key Executives
14.2.3. Product & Services
14.3. binx health, inc.
14.3.1. Business Overview
14.3.2. Key Executives
14.3.3. Product & Services
14.4. Biocartis NV
14.4.1. Business Overview
14.4.2. Key Executives
14.4.3. Product & Services
14.5. bioMérieux SA
14.5.1. Business Overview
14.5.2. Key Executives
14.5.3. Product & Services
14.6. Cardinal Health, Inc.
14.6.1. Business Overview
14.6.2. Key Executives
14.6.3. Product & Services
14.7. Co-Diagnostics, Inc.
14.7.1. Business Overview
14.7.2. Key Executives
14.7.3. Product & Services
14.8. Danaher Corporation
14.8.1. Business Overview
14.8.2. Key Executives
14.8.3. Product & Services
14.9. F. Hoffmann-La Roche AG
14.9.1. Business Overview
14.9.2. Key Executives
14.9.3. Product & Services
14.10. Genomadix
14.10.1. Business Overview
14.10.2. Key Executives
14.10.3. Product & Services
14.11. Lucira Health, Inc.
14.11.1. Business Overview
14.11.2. Key Executives
14.11.3. Product & Services
14.12. Meridian Bioscience Inc.
14.12.1. Business Overview
14.12.2. Key Executives
14.12.3. Product & Services
14.13. Novartis AG
14.13.1. Business Overview
14.13.2. Key Executives
14.13.3. Product & Services
14.14. OraSure Technologies, Inc.
14.14.1. Business Overview
14.14.2. Key Executives
14.14.3. Product & Services
14.15. Plexus Corp.
14.15.1. Business Overview
14.15.2. Key Executives
14.15.3. Product & Services
14.16. QIAGEN GmbH
14.16.1. Business Overview
14.16.2. Key Executives
14.16.3. Product & Services
14.17. Siemens Healthineers AG
14.17.1. Business Overview
14.17.2. Key Executives
14.17.3. Product & Services
14.18. Thermo Fisher Scientific Inc.
14.18.1. Business Overview
14.18.2. Key Executives
14.18.3. Product & Services
14.19. Visby Medical, Inc.
14.19.1. Business Overview
14.19.2. Key Executives
14.19.3. Product & Services
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing